Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Hiroyuki Yoda"'
Autor:
Miller Huang, Wanqi Fang, Alvin Farrel, Linwei Li, Antonios Chronopoulos, Nicole Nasholm, Bo Cheng, Tina Zheng, Hiroyuki Yoda, Megumi J. Barata, Tania Porras, Matthew L. Miller, Qiqi Zhen, Lisa Ghiglieri, Lauren McHenry, Linyu Wang, Shahab Asgharzadeh, JinSeok Park, W. Clay Gustafson, Katherine K. Matthay, John M. Maris, William A. Weiss
Publikováno v:
Cell Reports, Vol 43, Iss 3, Pp 113927- (2024)
Summary: Neuroblastoma is the most common extracranial solid tumor of childhood. While MYCN and mutant anaplastic lymphoma kinase (ALKF1174L) cooperate in tumorigenesis, how ALK contributes to tumor formation remains unclear. Here, we used a human st
Externí odkaz:
https://doaj.org/article/046ecfadd1a240a6bf1aaf35a0e740fe
Autor:
Akiko Tsujimoto, Niina Matsuo, Xiaoyi Lai, Takahiro Inoue, Hiroyuki Yoda, Jason Lin, Yoshinao Shinozaki, Takayoshi Watanabe, Nobuko Koshikawa, Atsushi Takatori, Hiroki Nagase
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 5821-5832 (2023)
Abstract Background Activating mutations of the KRAS occurs in >90% of pancreatic ductal adenocarcinoma (PDAC) cases. However, direct pharmacological targeting of the activated KRAS protein has been challenging. We previously reported that KR12, a DN
Externí odkaz:
https://doaj.org/article/703738c350c64285acb203fb3004436f
Autor:
Yusuke Mori, Ayaka Takeuchi, Kengo Miyagawa, Hiroyuki Yoda, Hiroaki Soda, Yoshihiro Nabeya, Naoko Watanabe, Toshinori Ozaki, Osamu Shimozato
Publikováno v:
FEBS Open Bio, Vol 11, Iss 5, Pp 1382-1394 (2021)
During the early phase of tumorigenesis, primary malignant cells survive within a low nutrition environment caused by a poorly organized vascular system. Here, we sought to determine the functional significance of CD133 in the survival of cancer cell
Externí odkaz:
https://doaj.org/article/fd8981ba8a1641748a451afe91318dea
Autor:
Masashi Matsushita, Yusuke Mori, Kyosuke Uchiumi, Takehiro Ogata, Mizuyo Nakamura, Hiroyuki Yoda, Hiroaki Soda, Nobuhiro Takiguchi, Yoshihiro Nabeya, Osamu Shimozato, Toshinori Ozaki
Publikováno v:
FEBS Open Bio, Vol 9, Iss 5, Pp 935-946 (2019)
Receptor‐type protein tyrosine phosphatase κ (PTPRK) is considered to be a candidate tumor suppressor. PTPRK dephosphorylates CD133, which is a stem cell marker; phosphorylated CD133 accelerates xenograft tumor growth of colon cancer cells through
Externí odkaz:
https://doaj.org/article/5dce7d4e79ee46b2909bba714dbb1660
Autor:
Yoko Ota, Hiroyuki Yoda, Takahiro Inoue, Takayoshi Watanabe, Yoshinao Shinozaki, Atsushi Takatori, Hiroki Nagase
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0257718 (2021)
Anaplastic lymphoma kinase (ALK) aberration is related to high-risk neuroblastomas and is an important therapeutic target. As acquired resistance to ALK tyrosine kinase inhibitors is inevitable, novel anti-ALK drug development is necessary in order t
Externí odkaz:
https://doaj.org/article/1d529d07ac064cc28b1c168739c8a509
Autor:
Hiroyuki Yoda, Toshimitsu Nakayama, Motofumi Miura, Masaharu Toriyama, Shigeyasu Motohashi, Takashi Suzuki
Publikováno v:
Biochemistry and Biophysics Reports, Vol 20, Iss , Pp - (2019)
Neuroblastoma is a pediatric malignant tumor arising from the sympathetic nervous system. The patients with high-risk neuroblastomas frequently exhibit amplification and high expression of the MYCN gene, resulting in worse clinical outcomes. Vitamin
Externí odkaz:
https://doaj.org/article/943dd79118574bd5a0c1c4afc61e9424
Autor:
Jason Lin, Sakthisri Krishnamurthy, Hiroyuki Yoda, Yoshinao Shinozaki, Takayoshi Watanabe, Nobuko Koshikawa, Atsushi Takatori, Paul Horton, Hiroki Nagase
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0215247 (2019)
In the search for new pharmaceutical leads, especially with DNA-binding molecules or genome editing methods, the issue of side and off-target effects have always been thorny in nature. A particular case is the investigation into the off-target effect
Externí odkaz:
https://doaj.org/article/8cffcabb95e24c59a33ec16c71c420ff
Autor:
Takehiro Ogata, Mizuyo Nakamura, Meijie Sang, Hiroyuki Yoda, Kiriko Hiraoka, Danjing Yin, Mexiang Sang, Osamu Shimozato, Toshinori Ozaki
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0179884 (2017)
Suberoylanilide hydroxamic acid (SAHA) represents one of the new class of anti-cancer drugs. However, multiple lines of clinical evidence indicate that SAHA might be sometimes ineffective on certain solid tumors including pancreatic cancer. In this s
Externí odkaz:
https://doaj.org/article/baa09445473d44f690347ae8215e726f
Autor:
Akiko Tsujimoto, Niina Matsuo, Xiaoyi Lai, Takahiro Inoue, Hiroyuki Yoda, Jason Lin, Yoshinao Shinozaki, Takayoshi Watanabe, Nobuko Koshikawa, Atsushi Takatori, Hiroki Nagase
Publikováno v:
Cancer Medicine. 12:5821-5832
Activating mutations of the KRAS occurs in90% of pancreatic ductal adenocarcinoma (PDAC) cases. However, direct pharmacological targeting of the activated KRAS protein has been challenging. We previously reported that KR12, a DNA-alkylating pyrrole-i
Autor:
Hiroki Nagase, Atsushi Takatori, Nobuko Koshikawa, Takayoshi Watanabe, Jason Lin, Yoshinao Shinozaki, Takahiro Inoue, Hiroyuki Yoda
Supplementary Materials and Methods and Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4249431962fd5c2e26adb35bed793b7
https://doi.org/10.1158/0008-5472.22422176.v1
https://doi.org/10.1158/0008-5472.22422176.v1